• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Consumer Cyclical·CRAB.JK
Share

PT Toba Surimi Industries Tbk Stocks

IDR 199Last Updated 16.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

IDR 23.28M

IDR 199
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Toba Surimi Industries Tbk is a prominent player in Indonesia's seafood processing industry. Its product portfolio encompasses a variety of pasteurized crab products, such as jumbo lump, super lump, special claw, and cocktail claw cuts. Beyond pasteurized offerings, the company also supplies an array of canned and frozen seafood, including fish, cephalopods, shellfish, and other value-added marine products. With a global reach, its exports serve key international markets including the United States, the European Community, Japan, Hong Kong, Canada, the United Kingdom, and Australia. Established in 1997, the company maintains its headquarters in Medan, Indonesia.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 20:13

Silence Therapeutics shares soared 125%. Merck is acquiring the cancer therapy developer

19.10.2026 18:43

"A buying opportunity is emerging": Nasdaq jumped 1% after the sell-off

19.10.2026 18:30

Analysts see 35% upside in label maker Brady on data center demand and Honeywell deal

19.10.2026 18:09

Goldman names 23 'unloved' defensive stocks as tech falters

19.10.2026 16:08

Morning in New York: Looking for a Foothold Ahead of Tech Giants' Earnings Reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026